OCP’s are C/I in pts receiving:
## **Core Concept**
Combined Oral Contraceptives (OCPs) are contraindicated in certain medical conditions due to the risk of adverse effects. These conditions often involve **thromboembolic events**, **liver disease**, or **other specific health risks** that can be exacerbated by the estrogen and progestin components of OCPs.
## **Why the Correct Answer is Right**
The correct answer involves understanding which medications or conditions necessitate caution or contraindication with OCPs. **Anticonvulsants/inducers of cytochrome P450** (such as rifampicin, phenytoin, and carbamazepine) can decrease the effectiveness of OCPs by inducing liver enzymes, which metabolize estrogen and progestins, thereby reducing their plasma levels. This can lead to reduced efficacy of the contraceptive and potentially cause breakthrough bleeding.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not specified, but generally, if it's not related to enzyme induction or a condition known to be worsened by OCPs, it's incorrect.
- **Option B:** Similarly, without specifics, if this option does not clearly relate to a known contraindication or interaction with OCPs (like significant liver disease, certain types of cancer, or severe hypertension), it's incorrect.
- **Option D:** Again, lacking details, if this doesn't directly pertain to a condition or drug interaction known to complicate OCP use, it's not the correct answer.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **enzyme-inducing drugs** (e.g., rifampicin, certain anticonvulsants) can significantly reduce the effectiveness of OCPs, necessitating either an alternative contraceptive method or a higher dose of the contraceptive. This is a critical consideration in patients with epilepsy or those taking medications for tuberculosis.
## **Correct Answer: C.**